Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: a systematic review and meta-analysis

EB Cunningham, A Wheeler, B Hajarizadeh… - International Journal of …, 2023 - Elsevier
Background With the advent of direct acting antiviral (DAA) therapies for the treatment of
hepatitis C virus (HCV), the World Health Organization recommended a goal to eliminate …

Hepatitis C guidance 2023 update: american association for the study of liver diseases–infectious diseases society of america recommendations for testing, managing …

D Bhattacharya, A Aronsohn, J Price… - Clinical Infectious …, 2023 - academic.oup.com
Abstract The Infectious Diseases Society of America and the American Association for the
Study of Liver Diseases have collaboratively developed evidence-based guidance …

EASL recommendations on treatment of hepatitis C: final update of the series☆

JM Pawlotsky, F Negro, A Aghemo, M Berenguer… - Journal of …, 2020 - Elsevier
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with
approximately 71 million chronically infected individuals worldwide. Clinical care for patients …

[HTML][HTML] Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1–6 and compensated cirrhosis: the EXPEDITION-8 trial

RS Brown Jr, M Buti, L Rodrigues, V Chulanov… - Journal of …, 2020 - Elsevier
Background & Aims Eight-week glecaprevir/pibrentasvir leads to high rates of sustained
virological response at post-treatment week 12 (SVR12) across HCV genotypes (GT) 1–6 in …

Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial

AH Litwin, PJ Lum, LE Taylor, SH Mehta… - The Lancet …, 2022 - thelancet.com
Background To achieve WHO targets for the elimination of hepatitis C virus (HCV) as a
public threat, an increased uptake of HCV treatment among people who inject drugs (PWID) …

Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: analysis of 5552 patients from 12 cohorts

A Mangia, S Milligan, M Khalili, S Fagiuoli… - Liver …, 2020 - Wiley Online Library
Background and aims Achieving sustained virological response (SVR; cure) in hepatitis C
patients using a simple regimen is key to making elimination by 2030 possible. In the largest …

Adherence to once-daily and twice-daily direct-acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist …

EB Cunningham, B Hajarizadeh, J Amin… - Clinical infectious …, 2020 - academic.oup.com
Background This study investigated adherence and associated factors among people with
recent injection drug use (IDU) or current opioid agonist therapy (OAT) and compared once …

Characteristics of persons treated for hepatitis C using national pharmacy claims data, United States, 2014–2020

EH Teshale, H Roberts, N Gupta… - Clinical Infectious …, 2022 - academic.oup.com
Using national pharmacy claims data for 2014–2020, 843 329 persons were treated for
hepatitis C at least once. The proportion treated increased annually among persons aged< …

Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study

M Heo, BL Norton, I Pericot-Valverde, SH Mehta… - Journal of …, 2024 - Elsevier
Background & Aims Direct-acting antivirals (DAAs) are highly effective for treating HCV
infection even among people who inject drugs (PWID). Yet, little is known about patients' …

Real-world hepatitis C treatment outcomes and reinfections among people who inject drugs at a needle and syringe program in Stockholm, Sweden

K Lindqvist, Z Thorin, M Kåberg - Harm Reduction Journal, 2023 - Springer
Background People who inject drugs (PWID) represent a population with an increased
prevalence of hepatitis C (HCV) infections. HCV treatment among PWID is essential to reach …